These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 5999513)

  • 41. [Prevention and treatment of hemopoietic disorders during the chemotherapy of malignant ovarian tumors].
    Rybalka AM
    Pediatr Akus Ginekol; 1979; (5):45-6. PubMed ID: 503619
    [No Abstract]   [Full Text] [Related]  

  • 42. Ifosfamide treatment of advanced ovarian cancer.
    Yazigi R; Wild R; Madrid J; Arraztoa J
    Obstet Gynecol; 1984 Feb; 63(2):163-6. PubMed ID: 6694809
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II clinical study of Yoshi 864 in epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.
    Slavik M; Muss H; Blessing JA; Delgado G
    Cancer Treat Rep; 1982 Sep; 66(9):1775-7. PubMed ID: 6288239
    [No Abstract]   [Full Text] [Related]  

  • 44. Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma.
    Erickson LD; Hartmann LC; Su JQ; Nielsen SN; Pfeifel DM; Goldberg RM; Levitt R; Stanhope CR
    Gynecol Oncol; 1994 Aug; 54(2):196-200. PubMed ID: 8063245
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot study.
    Davis AJ; Chapman W; Hedley DW; Oza AM; Tannock IF
    Cytometry A; 2003 Jan; 51(1):1-6. PubMed ID: 12500299
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of effects of cyclophosphamide, Cytembena, and Ypenyl in the treatment of inoperable ovarian carcinoma.
    Skoda V; Elis J; Jandová A; Laurová L; Novotná J; Perlík F
    Neoplasma; 1971; 18(5):471-2. PubMed ID: 5165867
    [No Abstract]   [Full Text] [Related]  

  • 47. Second malignancies from adjuvant chemotherapy? Too soon to tell.
    Henderson IC; Gelman R
    J Clin Oncol; 1987 Aug; 5(8):1135-7. PubMed ID: 3625242
    [No Abstract]   [Full Text] [Related]  

  • 48. [The effect of anesthesia and surgical intervention on hematopoiesis following chemotherapy of malignant ovarian tumors].
    Frid IA; Turbina IL
    Vopr Onkol; 1972; 18(2):91. PubMed ID: 4622345
    [No Abstract]   [Full Text] [Related]  

  • 49. [On bacteremia in patients with malignant ovarian neoplasms].
    Sokolova NM; Chen-Maĭransaeva TP; Klechikov LZ
    Vopr Onkol; 1969; 15(7):46-50. PubMed ID: 4897646
    [No Abstract]   [Full Text] [Related]  

  • 50. [Our experience with chemotherapy of carcinoma of the ovary].
    Zara C; Gilardi G
    Arch Ostet Ginecol; 1970; 75(3):226-34. PubMed ID: 5516882
    [No Abstract]   [Full Text] [Related]  

  • 51. [Antibody production and correlation of blood serum protein fractions in rabbits following administration of Dipin].
    Kovalev IE
    Farmakol Toksikol; 1965; 28(4):468-71. PubMed ID: 5868417
    [No Abstract]   [Full Text] [Related]  

  • 52. [Changes in the blood protein picture during the initial stages of neoplasms with particular reference to the forms of gynecologic involvement].
    Guarnieri E; Sibilla A; Biddau A
    Riv Ostet Ginecol; 1965 Jun; 20(6):413-22. PubMed ID: 5837075
    [No Abstract]   [Full Text] [Related]  

  • 53. [On some chromosome alterations in somatic cells observed during cytostatic therapy (cyclic phosphoamidic esters of nitrogen mustard)].
    Franceschini P; Grassi E
    Minerva Radiol; 1970; 15(1):38-43. PubMed ID: 5515160
    [No Abstract]   [Full Text] [Related]  

  • 54. [CHANGES OF BLOOD PROTEIN FRACTIONS IN PATIENTS WITH OVARIAN CANCER UNDERGOING CHEMOTHERAPY].
    KULIK GI; DANILENKO LP
    Vopr Onkol; 1965; 11():30-4. PubMed ID: 14300626
    [No Abstract]   [Full Text] [Related]  

  • 55. [Behavior of the serum protein pattern and of C-reactive protein in malignant tumors of the bladder].
    Frugoni A; Chianta A
    Minerva Urol; 1968; 20(2):64-8. PubMed ID: 5719091
    [No Abstract]   [Full Text] [Related]  

  • 56. [Anabolic treatment combined with an antimitotic agent in order to prevent leukocyte decrease].
    Biedermann C; Obolensky W; Scoglio P; Zürcher WO
    Ther Umsch; 1966 Dec; 23(12):509-15. PubMed ID: 5980438
    [No Abstract]   [Full Text] [Related]  

  • 57. [Blood albumin changes in malignant tumors].
    Dorrer R
    Landarzt; 1966 Jan; 42(2):51-2. PubMed ID: 5940669
    [No Abstract]   [Full Text] [Related]  

  • 58. [Changes in the serum protein picture in metastasizing ovarian carcinoma under the influence of cytostatic therapy (endoxan)].
    MURKEN J
    Z Geburtshilfe Gynakol; 1962 Jul; 159():90-8. PubMed ID: 14477377
    [No Abstract]   [Full Text] [Related]  

  • 59. [Protein fractions in the blood serum of cancer patients].
    Abasov IT
    Vopr Onkol; 1965; 11(7):41-7. PubMed ID: 5882660
    [No Abstract]   [Full Text] [Related]  

  • 60. [Changes in proteins and protein complexes of the blood serum in alveolar echinococcosis of the liver. (According to data of an expedition to the Yukatsk ASSR)].
    Alekseeva MI
    Med Parazitol (Mosk); 1965; 34(4):396-403. PubMed ID: 5871360
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.